- Home
- ICLR vs COO Comparison
ICLR vs COO Comparison
Compare ICLR & COO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- COO
- Stock Information
- Founded
- ICLR 1990
- COO 1980
- Country
- ICLR Ireland
- COO United States
- Employees
- ICLR N/A
- COO N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- COO Ophthalmic Goods
- Sector
- ICLR Health Care
- COO Health Care
- Exchange
- ICLR Nasdaq
- COO Nasdaq
- Market Cap
- ICLR 14.5B
- COO 14.6B
- IPO Year
- ICLR 1998
- COO N/A
- Fundamental
- Price
- ICLR $175.83
- COO $75.22
- Analyst Decision
- ICLR Buy
- COO Buy
- Analyst Count
- ICLR 13
- COO 9
- Target Price
- ICLR $210.67
- COO $96.89
- AVG Volume (30 Days)
- ICLR 1.2M
- COO 1.6M
- Earning Date
- ICLR 10-22-2025
- COO 08-27-2025
- Dividend Yield
- ICLR N/A
- COO N/A
- EPS Growth
- ICLR 13.11
- COO 21.77
- EPS
- ICLR 9.73
- COO 2.07
- Revenue
- ICLR $8,089,820,000.00
- COO $3,988,200,000.00
- Revenue This Year
- ICLR N/A
- COO $6.84
- Revenue Next Year
- ICLR $1.73
- COO $6.44
- P/E Ratio
- ICLR $18.06
- COO $36.34
- Revenue Growth
- ICLR N/A
- COO 6.88
- 52 Week Low
- ICLR $125.10
- COO $65.00
- 52 Week High
- ICLR $328.35
- COO $112.38
- Technical
- Relative Strength Index (RSI)
- ICLR 57.64
- COO 59.85
- Support Level
- ICLR $174.48
- COO $70.64
- Resistance Level
- ICLR $181.51
- COO $74.36
- Average True Range (ATR)
- ICLR 5.15
- COO 1.70
- MACD
- ICLR 0.16
- COO 0.38
- Stochastic Oscillator
- ICLR 78.82
- COO 95.70
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About COO The Cooper Companies Inc.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.